Windtree Therapeutics Inc Stock
Windtree Therapeutics Inc Stock price
Key metrics
| Market capitalization | $2.58m |
| Enterprise Value | $13.40m |
| P/E (TTM) P/E ratio | 0.00 |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 0.04 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-25.56m |
| Free Cash Flow (TTM) Free Cash Flow | $-15.30m |
| Cash position | $2.30m |
Is Windtree Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
Windtree Therapeutics Inc Stock Analysis
Analyst Opinions
1 Analyst has issued a forecast Windtree Therapeutics Inc:
Analyst Opinions
1 Analyst has issued a forecast Windtree Therapeutics Inc:
Financial data from Windtree Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.19 -0.19 |
54%
54%
|
|
| EBITDA | -25 -25 |
67%
67%
|
EBIT (Operating Income) EBIT | -26 -26 |
63%
63%
|
| Net Profit | -9.71 -9.71 |
61%
61%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Windtree Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Windtree Therapeutics Inc Stock News
Company Profile
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.
| Head office | United States |
| CEO | Jed Latkin |
| Employees | 15 |
| Founded | 1992 |
| Website | www.windtreetx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
